HONG KONG and SHANGHAI and FLORHAM PARK, N.J. — November 5, 2025 — Leads & Copy — HUTCHMED (China) Limited has completed patient enrollment in its global Phase III SAFFRON study. The study evaluates ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a chemotherapy-free, all-oral treatment for patients with epidermal growth factor receptor (“EGFR”)-mutated, MET-overexpressed and/or amplified, locally advanced or metastatic non-small cell lung cancer (“NSCLC”) following progression on treatment with TAGRISSO®.
The last patient was randomized on October 31, 2025. The combination, approved in China in June 2025 based on the SACHI trial, is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. Topline results are expected in the first half of 2026.
ORPATHYS® is an oral, potent and highly selective MET TKI. TAGRISSO® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC.
Investor Enquiries: +852 2121 8200 / ir@hutch-med.com
Media Enquiries: FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com; Ben Atwell / Tim Stamper +44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile); Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum: Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
Cavendish: Geoff Nash / Nigel Birks +44 20 7220 0500
Deutsche Numis: Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000
Source: HUTCHMED
